Uterine papillary serous carcinoma (UPSC) is an aggressive form of endometrial cancer characterized by a high recurrence rate and poor prognosis. We report a case of a 58-year-old post-menopausal woman with an abdominal wall metastasis in stage IA UPSC. After surgical staging, she did not receive additional adjuvant therapy. An egg sized palpable mass developed in the right lower abdomen after 8 months. Both Abdominopelvic computed tomography (CT) and positron emission tomography (PET)-CT revealed a metastatic lesion in the abdominal wall. Hence, surgical excision was performed. The pathological findings showed metastatic UPSC with clear resection margin. After the diagnosis of UPSC metastasis in the abdominal wall, she received chemotherapy utilizing paclitaxel and carboplatin. After 3 years, no evidence of recurrence was found. Therefore, we suggest that even when UPSC is confined to the endometrium without lymph node metastasis and without lymphovascular invasion, chemotherapy should be considered as a postoperative adjuvant therapy. 
Introduction
Uterine Papillary Serous Carcinoma (UPSC) is an uncommon but aggressive type of endometrial carcinoma with high recurrence rate and poor survival outcomes.
Although UPSC represents approximately 3% to 10% of the endometrial carcinomas, it accounts for almost 40% of all endometrial cancer-related death. The tumor often deeply invades the myometrium and has a propensity for peritoneal spread. Unfortunately, advanced-stage disease or recurrence is common even when UPSC is apparently only minimally invasive or even confined to the endometrium. 1~3 We report a case of a 58-year-old patient with abdominal wall metastasis in UPSC stage IA: no lymphovascular invasion and no metastasis in regional lymph nodes were present. 
Case Report

Discussion
Even among diseases that occur after menopause, UPSC is a highly malignant variant of endometrial adenocarcinoma that histologically and clinically resembles ovarian papillary serous carcinoma. It is usually found in an advanced stage. 4 Lymphovascular space invasion is common in the myometrium. The meticulous surgical staging is important for predicting the prognosis of UPSC, because most patients tend to be upstaged after a comprehensive surgical staging.
1,4~6
UPSC truly confined to the uterus has an overall excellent prognosis, whereas patients with extrauterine disease, even if it is revealed only in a microscopy, almost always suffers from recurrence and subsequent death caused by the tumor. (P = 0.04). 9 In GOG study 94, the 3-year disease-free and overall survival rates for the 60 patients with stage III papillary serous or clear cell carcinomas were 40.9% and 45.0%, respectively. 10 The data on whole abdominal radiation is somewhat encouraging, but effective systemic therapy is needed, because the rate of relapse is still substantial.
Trials investigating paclitaxel and carboplatin in UPSCs reported response rates of 60% to 70%. 11,12 Gehrig 13 reported that paclitaxel and platinum-based chemotherapy for three cycles followed by radiation therapy and then an additional three cycles of chemotherapy was tried for advanced-staged UPSC. The progression free survival in 9 patients was 46.4 months. stage IB patients who did not receive chemotherapy had recurrence. Platinum-based chemotherapy was associated with improved progression-free (P < 0.01) and overall survival (P < 0.05). In addition, no patient who received radiation to the vaginal cuff had recurrence at the cuff, but 6 of 31 (19%) patients who were not treated with vaginal radiation had recurrence at the cuff.
14 These retrospective, limited data supported the potential benefit of platinum-based chemotherapy with vaginal cuff irradiation in UPSC. A randomized, prospective study is needed to define optimal treatment stage I UPSC.
In conclusion, we report a case of UPSC abdominal wall metastasis. Systemic chemotherapy was an important aspect of the adjuvant therapy in our UPSC study. We suggest that even when UPSC is confined to the endometrium without regional lymph node metastasis and with no lymphovascular invasion, chemotherapy should be considered as a postoperative adjuvant therapy. Fig. 4 . Section of the excised mass from the abdominal wall discloses metastatic carcinoma with features of serous adenocarcinoma (H&E x400).
